Article Text

other Versions

PDF
Short Report
The performance of the Alere HIV combo point-of-care test on stored serum samples; useful for detection of early HIV-1 infections?
  1. Carla van Tienen1,
  2. Sharona Rugebregt1,
  3. Sandra Scherbeijn1,
  4. Hannelore Götz2,3,
  5. Corine Geurts van Kessel1
  1. 1Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands
  2. 2Department of STI Control and Sexual Health, Rotterdam-Rijnmond Public Health Service, Rotterdam, The Netherlands
  3. 3Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands
  1. Correspondence to Dr Carla van Tienen, Department of Viroscience, Erasmus Medical Center, Wytemaweg 80, Nb1052, Rotterdam 3015 CN, The Netherlands; c.vantienen{at}erasmusmc.nl;

Abstract

Introduction The Alere HIV-1/2 Antigen/Antibody Combo point-of-care test is a commercially available 4th-generation rapid test for the diagnosis of HIV infection, including acute infection. We evaluated the sensitivity of this test in samples from patients with acute, recent or chronic HIV-1 infection.

Methods A validation of the test was performed using 89 HIV-positive serum samples collected in 2008–2016, that were stored at −20°C. Twenty-three samples were only p24-positive (acute infection); 49 samples were antibody-positive and p24-positive (recent infection); 17 samples were only antibody-positive (chronic infection). HIV infection was confirmed by standard-of-care assays and PCR. Samples came from patients attending an outpatient clinic for STDs at the Public Health Department and from patients within the Erasmus Medical Center, Rotterdam, the Netherlands.

Results The overall sensitivity of the test for diagnosing HIV infection based on detection of p24 antigen and/or antibodies was 92% (95% CI 86% to 98%) (82/89). In acute sera with only p24 antigen positivity, the sensitivity of the test decreased to 65% (95% CI 46% to 85%) (15/23). When both antibody and antigen testing were positive, the p24 sensitivity was only 24% (95% CI 12% to 36%) (12/49), but in these sera the final test result was positive in all sera (49/49) due to the positive antibody component.

Conclusions In a laboratory setting, this test has an overall sensitivity of 92% to detect any stage of HIV-1 infection using sera specimens. It performs relatively well in detecting early HIV and may be beneficial as an initial screening in patients with a recent exposure to HIV. Additional testing in a laboratory setting remains mandatory as a proportion of acute HIV-1 infections are missed with this test.

  • HIV TESTING
  • P24
  • ANTIBODIES

Statistics from Altmetric.com

Footnotes

  • HG and CGvK contributed equally.

  • Handling editor Jackie A Cassell

  • Twitter Follow Carla van Tienen @carlavantienen

  • Contributors All authors have seen and approved the content of this manuscript. SR and SS tested and located the samples of this study. SR helped in analysing the data. SS has overseen the standard-of-care HIV laboratory testing in the past years and provided important information on these tests. HG and CGvK conceived and planned this study. CvT analysed the data and wrote the draft of the manuscript. HG and CGvK edited the manuscript.

  • Competing interests None declared.

  • Ethics approval Medical Ethical Committee Erasmus Medical Center (MEC-2015-306).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Previous work on a few samples was done using the previous version of the POCT, the Determine. These results are stored at our department and can be shared with persons who have a specific (research) interest in this field upon personal correspondence with the corresponding author.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.